Promising Durability Data Presented for BioVentrix’s Novel Heart Failure Treatment

Published: Oct 10, 2013

biotech jobs post your resume Help employers find you! Check out all the jobs and post your resume.

BioVentrix, a pioneer of technologies and procedures for less-invasive treatment of heart failure (HF), today announced the presentation of scientific data demonstrating the durability of its Revivent™ Myocardial Anchoring System in 24 patients one year post-procedure. These data, presented this week at the prestigious European Association for Cardio-Thoracic Surgery meeting in Vienna, Austria, by Dr. Andrew Wechsler, professor of cardiothoracic surgery at Drexel University (Philadelphia, Penn., USA), highlighted results from the Company’s Phase I clinical trial conducted at five European centers.

Help employers find you! Check out all the jobs and post your resume.

Back to news